Sysmex (OTCMKTS:SSMXY) Reaches New 12-Month Low - Should You Sell?

Key Points

• Sysmex Corporation's share price hit a new 52-week low of $15.20, closing at $15.52 with a trading volume of 1,636 shares.
• The company's quarterly earnings report revealed an EPS of $0.12, missing the consensus estimate of $0.16, along with revenue of $958.89 million, falling short of the expected $991.22 million.
• Sysmex has a market capitalization of $9.67 billion and continues to operate in the development and sale of diagnostic instruments and reagents in Japan.

Sysmex Corporation ADR (OTCMKTS:SSMXY - Get Free Report) reached a new 52-week low on Wednesday . The stock traded as low as $15.20 and last traded at $15.52, with a volume of 1636 shares changing hands. The stock had previously closed at $16.71.

Sysmex Price Performance

The stock has a market cap of $8.69 billion, a P/E ratio of 27.61 and a beta of 1.15. The company's 50 day moving average price is $16.74 and its 200-day moving average price is $17.80. The company has a quick ratio of 2.30, a current ratio of 2.97 and a debt-to-equity ratio of 0.12.

Sysmex (OTCMKTS:SSMXY - Get Free Report) last posted its quarterly earnings results on Wednesday, May 14th. The company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.16 by ($0.04). The firm had revenue of $958.89 million for the quarter, compared to the consensus estimate of $991.22 million. Sysmex had a return on equity of 10.36% and a net margin of 9.35%. As a group, sell-side analysts expect that Sysmex Corporation ADR will post 0.57 earnings per share for the current year.

Sysmex Company Profile

Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software in Japan. It offers three-part and five-part white blood cell differentiation instruments for use in hematology; and transport systems for high-volume testing in labs. The company also provides automated urine particle analyzers; automated blood coagulation analyzers; automated immunochemistry systems, which perform assays on minute sample quantities, as well as reagents to test for infectious disease and tumor markers; and flow cytometers to perform analysis in diagnosing leukemia, malignant lymphoma, and HIV/AIDS.